• English
• Español
• 中文
• Português

• Store Login
• Cart
• Support

• About USP
• USP–NF
• Food Chemicals Codex
• Pending & Non-U.S. Standards
• Reference Standards
• USP Verified
• Pharmacopeial Education
• Healthcare Quality and Information
  • Patient Safety
    • MEDMARX®
    • Medication Errors Reporting Program
    • Tools and resources
  • Healthcare Information
  • Patient Safety Standards
  • Practitioner Programs and Services
  • Safe Medication Practices and Research
• USP in Developing Countries
• Meetings
• Products

Learning from Practitioner Experience: Impact on the Implementation and Revision of USP Standards

Presented Tuesday June 7, 2000
American Society of Health-System Pharmacists
Annual Meeting 2000, Philadelphia, PA

The USP Practitioner and Product Experience Division receives information submitted voluntarily by health care practitioners and other stakeholders regarding the practical function of drug products and other health related articles in practice and patient care milieus. These data are collected via a network of reporting programs including the Drug Product Problem Reporting Program, which works toward identifying and improving defective, potentially unsafe drug products, and the USP Medication Errors Reporting Program*, which collects and analyzes potential and actual medication error reports. Both programs afford health professionals opportunity to confidentially report concerns. USP uses this valuable information to revise current legally recognized USP standards or to establish and implement new USP standards for drug products, packaging, and/or labeling that are recognized worldwide. Recent reports have prompted USP to institute revisions to the gentamicin endotoxin limit specification. Reported lipid based product errors prompted establishment of an ad hoc Subcommittee charged with formulating nomenclature for liposomal preparations. Impact of program reports on planned and future USP initiatives and USP Panel and Subcommittee endeavors is discussed. Furthermore, the manifest importance of practitioner experience to USP activities has prompted USP to conduct practitioner surveys when USP revisions are expected to greatly influence clinical practice. The rationale, status, and planned discourse of two surveys, proposed name changes to amrinone and amiodarone and proposed labeling and packaging requirements for neuromuscular blocking agents, is presented. Practitioners' shared experiences can help accomplish effective, practical change to drug standards and health care delivery systems and ultimately foster safer medication use.*

View the Poster  (532KB).